US pharma giant Eli Lilly has launched its highly anticipated diabetes and obesity drug, Mounjaro (tirzepatide), in India. The drug, available in 2.5 mg and 5 mg single-dose vials, is priced at ₹3,500 and ₹4,375, respectively. Since it is taken once a week, the monthly cost ranges from ₹14,000 to ₹17,500, significantly lower than the $1,000–$1,200 (₹86,000–1 lakh) price in the US.
The present study sought to establish how much type 2 diabetics manage their blood glucose and what influences their control. It was conducted at Dessie Hospital, Ethiopia, from February to March 2023 among 465 diabetic patients. The HbA1c test, which provides a long-term estimate of blood glucose levels, was used by the researchers rather than relying on fasting blood glucose alone.
The study explores how certain cells in mice that produce insulin (a hormone that regulates blood sugar) migrate to different organs and whether other organs, like the salivary glands, can help in insulin production. Scientists tracked the movement of these insulin-producing cells using genetic labeling techniques.
This study explores the correlation of surrogate measures of insulin resistance (IR) with coronary artery disease (CAD) among patients with type 2 diabetes (T2D). Since direct measures of IR are inconvenient and impractical in clinical settings, the study investigates simpler substitutes, which are triglyceride-glucose index (TyG), TyG-body mass index (TyG-BMI), TyG-waist circumference (TyG-WC), TyG-waist-to-height ratio (TyG-WHtR), metabolic score for insulin resistance (METS-IR), and the ratio of triglycerides/high-density lipoprotein cholesterol (TG/HDL-C). Among 2,702 T2D patients, the patients were divided into groups based on CAD status.
Novo Nordisk has released the findings of its REDEFINE 2 trial, which compared the new weight loss drug, CagriSema, in adults with type 2 diabetes and overweight or obesity. CagriSema consists of two drugs, cagrilintide and semaglutide, aimed at suppressing hunger and weight loss.
The researchers set out to find out how over-time variation in insulin resistance (IR) may influence the development of cardiovascular disease (CVD). Researchers studied data from a large Chinese health survey and used two key markers to measure IR: the triglyceride-glucose (TyG) index and the TyG-BMI index (which combines TyG with body mass index).
